Topper Copies

You are the Director of the National Bioethics Commission who is responsible for assessing the ethical feasibility and oversight of a nationwide gene sequencing program. The project named GeneFuture, aims to sequence the DNA of every newborn child and store it in a centralized national database. The objective is to identify genetic predispositions to serious diseases early in life, allowing for preventive treatment and personalized medicine. Over 100,000 babies have already been enrolled in the pilot phase of the program. The government claims that this move is a landmark step in public health advancement. However, collection of newborn genetic data raises significant ethical concerns, particularly around informed consent, which may not fully capture parents' understanding of the long-term risks involved. Once gathered, this sensitive data could be misused for purposes such as surveillance, insurance discrimination, or commercial marketing by third parties. Uncertainty over data ownership - whether it lies with the state, parents, or the individual as they mature - further complicates the issue. The involvement of private tech and pharmaceutical companies heightens fears of commercial exploitation, especially in the absence of clear mechanisms for individuals to withdraw consent or delete their genetic information upon reaching adulthood. (a) What are the ethical issues you perceive in the implementation of the GeneFuture program? (b) Identify the conflicting interests of different stakeholders in this case. (c) What guiding ethical principles would you recommend for implementation of this project?

Bhavika Chopra, AIR 25, 2025

As science advances, cultural norms take time to catch up, as propounded by William Ogburn in his theory of 'cultural lag'.

(a) Ethical issues with GeneFuture Programme 1. Lack of data sovereignty - children have no right/ability to consent 2. Use for public good - balance of rights v/s interests of public 3. Unclear consent withdrawal strategy - violates Right to Privacy 4. Concerns over ownership - undermines Article 21 5. Insurance discrimination due to increased risk - violates right to Health 6. Surveillance state - causing chilling effect and afraid citizenry 7. Commercial exploitation without benefits to participants

(b) Stakeholders and conflicting interests 1. State - formulation of policy and use for public health 2. Parents of children - give consent, but may be unaware of consequences 3. Children/Individuals - cannot consent or dissent 4. Pharmaceutical companies - technology development and research but benefits are privatised

Hence, a social cost to this issue along with privatised benefits creates problems for the GeneFuture Programme.

(c) Guiding principles for implementing programme 1. Public trust doctrine - state as trustee of gene information resource 2. Prevent identifiable data for use by commercial sector 3. Ensure highest standards of data security for storing data 4. Create Trust Fund for use by donors of gene data - based on profits accrued 5. Clear guidelines to withdraw consent post 18 years of age 6. Transparency at all stages: collection -> processing -> use, available to parents 7. Prevent sale of data to private companies 8. Ensure health benefits to those enrolled in pilot phase 9. Trust building - engage public stakeholders 10. Push for legal provisions for data safety under DPDP, 2023

Thus, the way to make this programme succeed is to uphold: 1. Principle of collegiality 2. Public Trust Doctrine 3. Constitutional morality (Right to Privacy) 4. Social contract and Public Good

A middle path as Gautama Buddha propounded is the ideal way to proceed - balancing rights and public health advancement.